期刊文献+

三磷酸腺苷结合转运蛋白G2与多重耐药及耐药逆转的研究进展 被引量:1

原文传递
导出
摘要 目的:为逆转三磷酸腺苷结合转运蛋白G2(ABCG2)介导的肿瘤多重耐药提供理论参考,更好地服务于新药开发及临床合理用药。方法:以"ABCG2""多重耐药""耐药逆转"为关键词检索近几年中国知网、万方数据库、PubMed数据库(关键词为相对应的英文),对所获得的文献进行整理、归纳和分析,综述ABCG2对多药耐药的作用及如何逆转耐药。结果与结论:ABCG2表达水平与肿瘤化疗效果有密切关系,其过表达可使多种抗癌药物外排最终导致多重耐药。目前逆转ABCG2介导的多重耐药成为国内外医药工作者热衷研究的方向。
作者 向阳芳 徐智
出处 《中国药房》 CAS CSCD 2014年第2期162-165,共4页 China Pharmacy
  • 相关文献

参考文献2

二级参考文献34

  • 1潘振奎,张力,张星,王欣,李宁,徐菲,常建华,管忠震.中国非小细胞肺癌患者表皮生长因子受体突变的研究[J].癌症,2005,24(8):919-923. 被引量:44
  • 2Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors [J]. J Natl Cancer Inst, 2000,92(3) :205-216.
  • 3Kosmidis P. Chemotherapy in NSCLC: histrocial review [J].Lung Cancer, 2002,38(Suppl 3):S19-S22.
  • 4Shepherd FA, Dancey J, Ramlau R, et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy [J]. J Clin Oncol, 2000,18(10): 2095-2103.
  • 5Fossella DV, DeVore R, Kerr RN, et al. Randomized phase Ⅲ trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previous treated with platinum-containing chemotherapy regimens [J]. J Clin Oncol,2000,18(12) :2354-2362.
  • 6Fukuoka M, Yano S, Giaccone G, et al. Multi-institutional randomized phase Ⅱ trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer [J]. J Clin Oncol, 2003,21 (12): 2237-2246.
  • 7Kris MG, Natale RB, Herbst RS, et al. Efficacy of gefitinib,an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer [J]. JAMA, 2003,290(16) :2149-2158.
  • 8Lynch, T, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying resensiveness of non-small-cell lung cancer to gefitinib [J]. N Engl J Med,2004,350(21 ): 2129-2139.
  • 9Paez JG, Janne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy [J]. Science, 2004,304(5676): 1497-1500.
  • 10Huang SF, Liu HP, Li LH, et al. High frequency of epidermal growth factor receptor mutations with complex patterns in nonsmall cell lung cancers related to gefitinib responsiveness in Taiwan [J]. Clin Cancer Res, 2004, 10(24) :8195-8203.

共引文献121

同被引文献3

引证文献1

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部